Pharma Industry

The rise in profits was attributed to the robust performance in international markets and growth in new launches from Emcure's in-house portfolio

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Rising API prices from China and feedstock disruptions amid the West Asia crisis are tightening cost pressures on India's pharma sector despite temporary inventory buffers

Govt urges pharma firms to cut import reliance, boost domestic production and diversify exports as data shows rising foreign value addition and heavy dependence on China and the US

The deal creates Apothecon Group, a specialty pharma company focused on regulated markets in the US, Europe and India, with plans to expand its pipeline, footprint and acquisitions

Indian pharma market's growth was led more by price increases that an uptick in consumption

Pharma firm acquires office units in Parinee I building as Mumbai office market sees rising absorption, lower vacancies, and steady growth in rentals

Indian pharmaceutical exports stood at nearly USD 29 billion up to February this financial year registering a growth of five per cent compared to the same period last year, a top official said on Saturday. K Raja Bhanu, Director General, Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) said the sector, currently valued at approximately USD 60 billion, is projected to grow to USD 130 billion by 2030. "Inspite of global challenges, pharmaceuticals exports have been one of the few sectors that has maintained its growth momentum. Pharmaceutical exports during the period AprilFebruary FY26 stood at USD 28.29 billion, reflecting a growth of 5.6 per cent compared to the same period in FY25 led by formulations, biologicals, vaccines and Ayush products," he said. The official further said the exports reached USD 30.47 billion in FY 202425, reflecting a growth of 9.4 percent year on year despite global pricing pressures and trade volatilities..

Duties for products made by certain larger companies will take effect in 120 days, while items from smaller manufacturers won't be hit for another 180 days, according to a White House statement

A week before semaglutide's patent expiry, the CDSCO issued an advisory warning pharma companies against promoting prescription weight-loss drugs, banned by law

Pharmaceutical companies are increasingly turning to AI to accelerate R&D, betting on new modelling tools and automated labs to unlock efficiency gains across their pipeline

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

As cheaper GLP-1 weight-loss drugs flood India after patent expiry, the government has intensified surveillance to curb illegal sales, misleading promotion, and unsafe use without medical supervision

Uttar Pradesh is ramping up investments in pharma parks and medical device manufacturing to emerge as a major healthcare production hub in South Asia

Small pharma firms have flagged a steep surge in raw material and packaging costs amid global disruptions, warning of supply risks and seeking price controls

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.

In a move aimed at speeding up approvals for new drugs, the government has changed the way testing permissions are granted, allowing companies to begin laboratory testing immediately after filing applications instead of waiting for detailed scrutiny. In an official circular, the country's apex drug regulatory authority, Central Drugs Standard Control Organization (CDSCO), said it has decided that "No Objection Certificate (NOC) for testing of drug samples at the designated laboratories (IPC, Ghaziabad; CDTL, Mumbai; CDL at CRI, Kasauli; or NIB, Noida) shall be issued immediately upon receipt of applications in the concerned division." Earlier, the regulator examined detailed specifications submitted by applicants before issuing permission for testing. These included "Type of formulation, dosage form, Critical Quality Attributes (CQAs), and general characteristics of the product," along with "Product development reports, forced degradation studies, and other relevant data, in ...

At the IPA summit, pharma leaders said India's 2047 ambitions depend on embedding AI, strengthening trust and accelerating innovation, as speed and quality become the sector's defining advantages

India's drug regulator is withdrawing export NOC requirements for SRA markets and easing other low-risk approvals, even as it strengthens oversight of manufacturing quality